glp-1 medication New Guidelines for Type 2 Diabetes in 2025 As Interest in GLP-1 Drugs

Our blog series on GLP-1 agonists for weight loss is aimed at unpacking the science behind this new frontier in weight management, presenting a detailed overview of how they work, their efficacy, and their role in a holistic approach to health and wellness.

Compounded semaglutide/tirzepatide will phase out by late May 2025, so prepare to switch to FDA-approved products

Conclusion GLP-1RAs show significant promise as a potential disease-modifying therapy for neurodegenerative and inflammatory eye diseases, acting through both systemic metabolic improvements and direct ocular mechanisms, representing a paradigm shift beyond their metabolic indications.

Expert Guidance Available in Coral Gables and Pinecrest, FL.

Important Program Disclaimer